As a time-honored pharmaceutical enterprise, The Le’s Group has made a forward-looking strategic layout for the development of the stem cell industry. Building on its strengths in the TCM industry and leveraging international advanced stem cell technologies, the Group focuses on the regenerative medicine sector. It strives to integrate traditional Chinese medicine with cutting-edge biotechnologies of stem cells, blazing an innovative path for time-honored Chinese pharmaceutical enterprises.

Guided by the tenet of "Carry Forward TCM Culture" and the mission of "Technology Empowers TCM, Making Health Accessible to All", the Group develops an integrated online-and-offline complex for chronic disease conditioning with custom formulas and targeted remedies for chronic illnesses.

Pharmaceutical Factory under The Le’s Group — Henan Shizhen Pharmaceutical

Shizhen Pharmaceutical integrates modern technologies with traditional Chinese medical wisdom. Market-oriented, it carries out R&D and manufacturing backed by The Le’s Group’s robust research capabilities. Its 72 product lines including Qingre Jiedu Tablets and Concentrated Liuwei Dihuang Pills have won wide market recognition. Sales coverage spans 25 provinces, municipalities and autonomous regions in China, and the factory supplies major medical institutions in Beijing, Shanghai and other cities. Signature preparations such as Angong Niuhuang Wan, Wuji Baifeng Wan and Niuhuang Qingxin Wan are exported to the United States, South Korea, Southeast Asia and other countries and regions, enjoying high popularity among overseas clients.

Second Pharmaceutical Factory under The Le’s Group — Shanghai Yunfeng Pharmaceutical Co., Ltd.

The acquisition of Shanghai Yunfeng Pharmaceutical Co., Ltd. marks a key step for The Le’s Group to optimise its strategic layout and resource allocation in the TCM, big health and wellness & elderly care industries. It will further deepen the integration of pharmaceutical, medical and wellness-elderly care services, expand the scope of health and elderly care services, build a comprehensive medical-elderly care operation model, and accelerate the Group’s progress towards its medium and long-term development goal of becoming a TCM manufacturer.